BPC-157: What the Research Actually Shows About Gut Healing and Tissue Repair

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a sequence found in human gastric juice. BPC-157 has attracted significant interest in peptide research circles for its reported effects on gastrointestinal healing and connective tissue repair, but the evidence base requires careful examination. This profile from the Peptide Register summarises what the published literature actually shows, where the gaps are, and what the current regulatory landscape looks like.

What Is BPC-157 and How Is It Proposed to Work?

BPC-157 is a partial sequence of a larger protein called BPC, which is naturally present in human gastric juice at very low concentrations. The synthetic peptide does not occur in nature in its isolated form. BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids derived from human gastric juice protein. Researchers have proposed several mechanisms of action, including upregulation of growth factor expression (notably VEGF and EGF), modulation of the nitric oxide system, and interaction with the dopaminergic and GABAergic pathways. BPC-157 has been studied primarily in rodent models across a range of injury types, and much of what is claimed about this peptide traces back to a single research group based in Zagreb, Croatia. For readers seeking foundational context on how peptides differ from other biological molecules, the Peptide Register offers a detailed guide on how peptides differ from proteins, hormones, and small molecules.

Gastrointestinal Research: What Animal Studies Report

The bulk of published BPC-157 research focuses on gastrointestinal models. In rodent studies, BPC-157 has been reported to accelerate healing of gastric ulcers, reduce inflammation in experimentally induced colitis, and protect against NSAID-induced gut damage. BPC-157 has shown gastroprotective effects in multiple rodent models of ulcers, colitis, and NSAID-induced gut damage. Several studies from the Sikiric laboratory in Croatia have reported that BPC-157 administration in rats reduced lesion size and promoted mucosal integrity across various injury models.

However, these findings carry important caveats. The majority of gastrointestinal BPC-157 studies originate from a single laboratory group in Zagreb. Independent replication by other research teams remains limited. The majority of published BPC-157 research comes from a single research group, and independent replication remains limited. Sample sizes in most studies are small, typically involving 6 to 12 animals per group. No peer-reviewed, controlled human clinical trials on BPC-157 for gastrointestinal conditions have been published as of mid-2025. These are important considerations that the Peptide Register highlights for researchers evaluating the strength of the evidence. For more on interpreting study quality, see our guide on how to read peptide research.

Tendon, Muscle, and Connective Tissue Studies

Beyond the gut, BPC-157 has been investigated in animal models of tendon transection, ligament injury, muscle crush injury, and bone fracture. BPC-157 has been reported to accelerate tendon and ligament healing in rat models of transection and crush injury. In rat studies, BPC-157 treatment groups showed faster recovery of tensile strength in Achilles tendon transection models compared to controls. Rodent studies have also reported improved healing outcomes in models of muscle damage and bone fracture.

Again, these are exclusively animal studies. No controlled human trials have examined BPC-157 for musculoskeletal repair. No controlled human clinical trials have been published on BPC-157 for musculoskeletal or gastrointestinal conditions as of mid-2025. The translational relevance of these rodent findings to human physiology is uncertain, as dosing, metabolism, and tissue biology differ substantially between species.

Regulatory Status and Safety Considerations

BPC-157 is not approved by the FDA, TGA, or EMA for any therapeutic indication. In the United States, the FDA placed BPC-157 on its Category 2 list in 2024, which restricts its use in compounding pharmacies pending further review. BPC-157 is not approved for human therapeutic use by the FDA, TGA, or EMA in any jurisdiction. In Australia, peptides like BPC-157 fall under prescription-only scheduling, and accessing them legally requires a prescriber; the Peptide Register maintains a licensed provider directory for reference. For more detail on how regulatory frameworks are evolving, see the post on peptide regulation around the world.

BPC-157 has shown a favourable safety profile in the animal studies conducted to date, with no major adverse effects reported at tested doses. However, no long-term human safety data exist. BPC-157 has shown a favourable safety profile in animal studies, but no long-term human safety data exist. The absence of Phase I through Phase III human trials means that safety, pharmacokinetics, and efficacy in humans are not established.

Summary: A Peptide With Preclinical Interest but Significant Evidence Gaps

BPC-157 represents one of the more extensively studied peptides in preclinical research, with a body of animal data suggesting effects on gastrointestinal protection and tissue repair. BPC-157 is one of the most frequently discussed peptides in preclinical research, yet it lacks any completed human clinical trial. The Peptide Register catalogues BPC-157 alongside other peptides in its peptide database to help researchers and clinicians assess the current evidence objectively. The gap between preclinical promise and clinical validation remains wide, and readers should weigh claims about BPC-157 accordingly.